Literature DB >> 24003006

High rates of comorbid depressive and anxiety disorders among women with premutation of the FMR1 gene.

Heather A Kenna1, Molly Tartter, Scott S Hall, Amy A Lightbody, Quynh Nguyen, C Paula de los Angeles, Allan L Reiss, Natalie L Rasgon.   

Abstract

Phenotypic variations are emerging from investigations of carriers of the fragile X mental retardation 1 (FMR1) premutation gene (55 to 200 CGG repeats). Initial studies suggest elevated psychiatric and reproductive system dysfunction, but have largely used self-reports for assessment of psychiatric history. The present study used diagnostic psychiatric interviews and assessed reproductive and menstrual history in women with FMR1 premutation. History of psychiatric diagnoses and data on reproductive functioning were collected in 46 women with FMR1 premutation who were mothers of at least one child with the fragile X full mutation. Results showed a significantly earlier age of menopause (mean age = 45.6 years) relative to the national average age of menopause (mean age = 51 years) and a high rate (76%) of lifetime depressive or anxiety history, with 43% of the overall sample reporting a comorbid history of both diagnoses. Compared to those free of psychiatric history, significantly longer premutation length was observed among women with psychiatric history after adjusting for age, with comorbid women having the highest number of CGG repeats (mean = 95.8) compared to women free of psychiatric history (mean = 79.9). Psychiatric history did not appear significantly related to reproductive system dysfunction, though results may have been obscured by the high rates of psychiatric dysfunction in the sample. These data add to the growing evidence base that women with the FMR1 premutation have an increased risk of psychiatric illness and risk for early menopause. Future investigations may benefit from inclusion of biochemical reproductive markers and longitudinal assessment of psychiatric and reproductive functioning.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  FMR1 premutation; anxiety; depressive disorders; menopause; women

Mesh:

Substances:

Year:  2013        PMID: 24003006      PMCID: PMC5756731          DOI: 10.1002/ajmg.b.32196

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  32 in total

1.  Evidence of early ovarian aging in fragile X premutation carriers.

Authors:  C K Welt; P C Smith; A E Taylor
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

2.  Prevalence of CGG expansions of the FMR1 gene in a US population-based sample.

Authors:  Marsha Mailick Seltzer; Mei Wang Baker; Jinkuk Hong; Matthew Maenner; Jan Greenberg; Daniel Mandel
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-22       Impact factor: 3.568

3.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

4.  Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers.

Authors:  James A Bourgeois; Andreea L Seritan; E Melina Casillas; David Hessl; Andrea Schneider; Ying Yang; Inderjeet Kaur; Jennifer B Cogswell; Danh V Nguyen; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2010-08-24       Impact factor: 4.384

5.  Prospective study of factors influencing the onset of natural menopause.

Authors:  I Kato; P Toniolo; A Akhmedkhanov; K L Koenig; R Shore; A Zeleniuch-Jacquotte
Journal:  J Clin Epidemiol       Date:  1998-12       Impact factor: 6.437

6.  Menopausal transition, mood, and cognition: an integrated view to close the gaps.

Authors:  Claudio N Soares; Pauline M Maki
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

7.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

8.  Evidence of depressive symptoms in fragile-X syndrome premutated females.

Authors:  Laia Rodriguez-Revenga; Irene Madrigal; Montserrat Alegret; Mónica Santos; Montserrat Milà
Journal:  Psychiatr Genet       Date:  2008-08       Impact factor: 2.458

Review 9.  Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines.

Authors:  Elizabeth Berry-Kravis; Liane Abrams; Sarah M Coffey; Deborah A Hall; Claudia Greco; Louise W Gane; Jim Grigsby; James A Bourgeois; Brenda Finucane; Sebastien Jacquemont; James A Brunberg; Lin Zhang; Janet Lin; Flora Tassone; Paul J Hagerman; Randi J Hagerman; Maureen A Leehey
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

10.  Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1.

Authors:  P Franke; M Leboyer; M Gänsicke; O Weiffenbach; V Biancalana; P Cornillet-Lefebre; M F Croquette; U Froster; S G Schwab; F Poustka; M Hautzinger; W Maier
Journal:  Psychiatry Res       Date:  1998-08-17       Impact factor: 3.222

View more
  16 in total

1.  Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause.

Authors:  Wendy K Marsh; Joyce T Bromberger; Sybil L Crawford; Katherine Leung; Howard M Kravitz; John F Randolph; Hadine Joffe; Claudio N Soares
Journal:  Menopause       Date:  2017-12       Impact factor: 2.953

2.  Broad autism spectrum and obsessive-compulsive symptoms in adults with the fragile X premutation.

Authors:  A Schneider; C Johnston; F Tassone; S Sansone; R J Hagerman; E Ferrer; S M Rivera; D Hessl
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

3.  Improving Health Education for Women Who Carry an FMR1 Premutation.

Authors:  Whitney Espinel; Krista Charen; Lillie Huddleston; Jeannie Visootsak; Stephanie Sherman
Journal:  J Genet Couns       Date:  2015-07-16       Impact factor: 2.537

4.  Health knowledge of women with a fragile X premutation: Improving understanding with targeted educational material.

Authors:  Liana Smolich; Krista Charen; Stephanie L Sherman
Journal:  J Genet Couns       Date:  2020-01-30       Impact factor: 2.537

5.  Maternal Consequences of the Detection of Fragile X Carriers in Newborn Screening.

Authors:  Donald B Bailey; Anne Wheeler; Elizabeth Berry-Kravis; Randi Hagerman; Flora Tassone; Cynthia M Powell; Myra Roche; Louise W Gane; John Sideris
Journal:  Pediatrics       Date:  2015-07-13       Impact factor: 7.124

Review 6.  Fragile X spectrum disorders.

Authors:  Reymundo Lozano; Carolina Alba Rosero; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2014-11

7.  Trajectory and Predictors of Depression and Anxiety Disorders in Mothers With the FMR1 Premutation.

Authors:  Jane E Roberts; Bridgette L Tonnsen; Lindsay M McCary; Amy L Ford; Robert N Golden; Donald B Bailey
Journal:  Biol Psychiatry       Date:  2015-07-31       Impact factor: 13.382

8.  Maternal predictors of anxiety risk in young males with fragile X.

Authors:  Bridgette L Tonnsen; Kim M Cornish; Anne C Wheeler; Jane E Roberts
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2014-05-16       Impact factor: 3.568

Review 9.  The cognitive neuropsychological phenotype of carriers of the FMR1 premutation.

Authors:  Jim Grigsby; Kim Cornish; Darren Hocking; Claudine Kraan; John M Olichney; Susan M Rivera; Andrea Schneider; Stephanie Sherman; Jun Yi Wang; Jin-Chen Yang
Journal:  J Neurodev Disord       Date:  2014-07-30       Impact factor: 4.025

10.  In the Gray Zone in the Fragile X Gene: What are the Key Unanswered Clinical and Biological Questions?

Authors:  Deborah A Hall
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.